SCHEMBL18919366

SCHEMBL18919366

CC(=O)N(C(C)=O)C(=O)c1ccccc1C(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.57
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.47
ALDH1A1 P00352 2/20 0.46
CDC25B P30305 2/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 1/20 0.45
NR4A1 P22736 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MYC P01106 1/20 0.43
ELANE P08246 1/20 0.42
CDC25A P30304 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13183116 0.81 AKR1C3 (0.61) AKR1C3GAAMAPTTSHRALDH1A1
SCHEMBL17712467 0.80 CES2 (0.39) AKR1C3GAAMAPTTSHRALDH1A1
SCHEMBL9725154 0.80 CES2 (0.50) MAPTTSHRALDH1A1POLBHPGD
SCHEMBL700595 0.79 AKR1C3 (0.85) AKR1C3GAAMAPTTSHRALDH1A1
SCHEMBL29447165 0.79 AKR1C3 (0.85) AKR1C3GAAMAPTTSHRALDH1A1
SCHEMBL3305342 0.79 AKR1C3 (0.59) AKR1C3GAAMAPTTSHRALDH1A1
SCHEMBL822891 0.78 AKR1C3 (0.68) AKR1C3GAAMAPTALDH1A1CDC25B
SCHEMBL28883310 0.77 AKR1C3 (0.81) AKR1C3GAAMAPTALDH1A1CDC25B
Fluoride SCHEMBL28319246 0.77 AKR1C3 (0.81) AKR1C3GAAMAPTALDH1A1CDC25B
SCHEMBL13159280 0.76 HPGD (0.69) AKR1C3GAAMAPTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171602-A2 CCR8 ANTIBODIES AND USES THEREOF Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4171601-A2 SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4172201-A2 CHEMOKINE RECEPTOR ANTIBODIES BINDING SULFATED TRD MOTIFS Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4172204-A2 CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4172202-A2 ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
WO-2021260210-A2 ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES BAYER AKTIENGESELLSCHAFT (DE) 2021-12-30 WO disclosed
WO-2021260208-A2 SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION BAYER AKTIENGESELLSCHAFT (DE) 2021-12-30 WO disclosed
WO-2021260206-A2 CHEMOKINE RECEPTOR ANTIBODIES BINDING SULFATED TRD MOTIFS BAYER AKTIENGESELLSCHAFT (DE) 2021-12-30 WO disclosed
WO-2021260209-A2 CCR8 ANTIBODIES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2021-12-30 WO disclosed
WO-2021152186-A2 CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS BAYER AKTIENGESELLSCHAFT (DE) 2021-08-05 WO disclosed
EP-3383909-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Inc. (US) 2018-10-10 EP disclosed
EP-3383910-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Inc. (US) 2018-10-10 EP disclosed
WO-2017095808-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC. (US) 2017-06-08 WO disclosed
WO-2017095805-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC. (US) 2017-06-08 WO disclosed